These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

119 related items for PubMed ID: 39163928

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Investigations on the Mechanism of Magnesium Stearate to Modify Aerosol Performance in Dry Powder Inhaled Formulations.
    Jetzer MW, Schneider M, Morrical BD, Imanidis G.
    J Pharm Sci; 2018 Apr; 107(4):984-998. PubMed ID: 29247741
    [Abstract] [Full Text] [Related]

  • 4. Preparation and Evaluation of Surface Modified Lactose Particles for Improved Performance of Fluticasone Propionate Dry Powder Inhaler.
    Singh DJ, Jain RR, Soni PS, Abdul S, Darshana H, Gaikwad RV, Menon MD.
    J Aerosol Med Pulm Drug Deliv; 2015 Aug; 28(4):254-67. PubMed ID: 25517187
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Role of dispersion enhancer selection in the development of novel tratinterol hydrochloride dry powder inhalation formulations.
    Liu T, Tong S, Liao Q, Pan L, Cheng M, Rantanen J, Cun D, Yang M.
    Int J Pharm; 2023 Mar 25; 635():122702. PubMed ID: 36773729
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Dispersibility of lactose fines as compared to API in dry powders for inhalation.
    Thalberg K, Åslund S, Skogevall M, Andersson P.
    Int J Pharm; 2016 May 17; 504(1-2):27-38. PubMed ID: 26965200
    [Abstract] [Full Text] [Related]

  • 9. Effect of magnesium stearate surface coating method on the aerosol performance and permeability of micronized fluticasone propionate.
    Kumar V, Sethi B, Yanez E, Leung DH, Ghanwatkar YY, Cheong J, Tso J, Narang AS, Nagapudi K, Mahato RI.
    Int J Pharm; 2022 Mar 05; 615():121470. PubMed ID: 35041913
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Insights into the roles of carrier microstructure in adhesive/carrier-based dry powder inhalation mixtures: Carrier porosity and fine particle content.
    Shalash AO, Molokhia AM, Elsayed MM.
    Eur J Pharm Biopharm; 2015 Oct 05; 96():291-303. PubMed ID: 26275831
    [Abstract] [Full Text] [Related]

  • 12. Influence of fine lactose and magnesium stearate on low dose dry powder inhaler formulations.
    Guchardi R, Frei M, John E, Kaerger JS.
    Int J Pharm; 2008 Feb 04; 348(1-2):10-7. PubMed ID: 17689898
    [Abstract] [Full Text] [Related]

  • 13. Powder flow analysis: A simple method to indicate the ideal amount of lactose fines in dry powder inhaler formulations.
    Hertel M, Schwarz E, Kobler M, Hauptstein S, Steckel H, Scherließ R.
    Int J Pharm; 2018 Jan 15; 535(1-2):59-67. PubMed ID: 29100914
    [Abstract] [Full Text] [Related]

  • 14. Agglomerate behaviour of fluticasone propionate within dry powder inhaler formulations.
    Le VN, Robins E, Flament MP.
    Eur J Pharm Biopharm; 2012 Apr 15; 80(3):596-603. PubMed ID: 22198291
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Dry powder inhalers: study of the parameters influencing adhesion and dispersion of fluticasone propionate.
    Le VN, Hoang Thi TH, Robins E, Flament MP.
    AAPS PharmSciTech; 2012 Jun 15; 13(2):477-84. PubMed ID: 22399285
    [Abstract] [Full Text] [Related]

  • 18. Correlations between surface composition and aerosolization of jet-milled dry powder inhaler formulations with pharmaceutical lubricants.
    Mangal S, Park H, Nour R, Shetty N, Cavallaro A, Zemlyanov D, Thalberg K, Puri V, Nicholas M, Narang AS, Zhou QT.
    Int J Pharm; 2019 Sep 10; 568():118504. PubMed ID: 31299339
    [Abstract] [Full Text] [Related]

  • 19. Influence of the lactose grade within dry powder formulations of fluticasone propionate and terbutaline sulphate.
    Le VN, Bierend H, Robins E, Steckel H, Flament MP.
    Int J Pharm; 2012 Jan 17; 422(1-2):75-82. PubMed ID: 22036653
    [Abstract] [Full Text] [Related]

  • 20. Performance tuning of particle engineered mannitol in dry powder inhalation formulations.
    Hertel N, Birk G, Scherließ R.
    Int J Pharm; 2020 Aug 30; 586():119592. PubMed ID: 32622814
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 6.